ArticleFrontiers in oncology2026
Long-term outcomes of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for postoperative locoregional recurrent esophageal cancer: a prospective phase II study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative locoregional recurrence of esophageal cancer remains a major clinical challenge, with no established standard salvage treatment. Although definitive chemoradiotherapy (CRT) is widely used, outcomes with conventional platinum plus 5-fluorouracil (FP) regimens remain unsatisfactory. This phase II study aimed to evaluate the efficacy and safety of CRT combined with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT). Methods: In this single-arm, prospective phase II trial, 29 patients with postoperative locoregional recurrent esophageal cancer without distant metastasis were enrolled between 2015 and 2023. All patients received radiotherapy (60 Gy in 30 fractions) with concurrent DCF chemotherapy. The primary endpoint was progression-free survival (PFS), compared with a historical control of 12 months. Secondary endpoints included overall survival (OS) and treatment-related toxicities. Results: With a median observation period for survivors of 77.5 months, the median PFS was 48.0 months, substantially exceeding the predefined threshold. The 3-year and 5-year PFS rates were 55.2% and 49.7%, respectively. The 3-year and 5-year OS rates were 75.2% and 58.8%, respectively. Treatment compliance was high, with 89.7% of patients completing the planned regimen without dose reduction. Grade 4 hematologic toxicities occurred in 3 patients, and one patient developed grade 3 heart failure. No grade ≥2 late adverse events were observed. Conclusions: DCF-based chemoradiotherapy demonstrated durable disease control and a favorable safety profile in patients with postoperative locoregional recurrent esophageal cancer. Given the substantial improvement in long-term survival compared with historical outcomes, this regimen may represent a promising curative-intent salvage strategy. Further validation in randomized controlled trials is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.